• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

147.83 UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EST, Mar 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,755
Open 147.83
Bid (Size) 146.35 (100)
Ask (Size) 147.50 (200)
Prev. Close 147.83
Today's Range 147.83 - 147.83
52wk Range 93.37 - 157.29
Shares Outstanding 1,253,809,440
Dividend Yield 2.14%
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Compugen (CGEN) Q4 2025 Earnings Call Transcript ↗
March 02, 2026
Compugen (CGEN) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia
March 02, 2026
From Gilead Sciences, Inc.
Via Business Wire

Performance

YTD
+21.6%
+21.6%
1 Month
+3.5%
+3.5%
3 Month
+19.3%
+19.3%
6 Month
+31.2%
+31.2%
1 Year
+27.5%
+27.5%

More News

Read More
News headline image
Arcellx President Sells $10 Million Worth of Shares After Acquisition Announcement ↗
March 02, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Arcellx President Sells $10M Worth of Shares After Acquisition Announcement ↗
March 02, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
P/E Ratio Insights for Gilead Sciences ↗
February 27, 2026
Via Benzinga
What's going on in today's session: S&P500 movers ↗
February 27, 2026
Via Chartmill
Uncover the latest developments among S&P500 stocks in today's session. ↗
February 27, 2026
Via Chartmill
News headline image
Gilead Sciences Stock: Is GILD Outperforming the Healthcare Sector?
February 27, 2026
Via Barchart.com
Topics ETFs
News headline image
Kymera (KYMR) Q4 2025 Earnings Call Transcript ↗
February 26, 2026
Via The Motley Fool
Topics Earnings
News headline image
Merck's Two-Drug HIV Regimen Challenges Industry Standards Following Positive Phase 3 Results
February 26, 2026
Via MarketMinute
Topics Intellectual Property
News headline image
Arcus (RCUS) Q4 2025 Earnings Call Transcript ↗
February 25, 2026
Via The Motley Fool
Topics Earnings
News headline image
Gilead’s Twice-Yearly HIV Breakthrough: A Paradigm Shift in Global Prevention and Market Dominance
February 25, 2026
Via MarketMinute
Topics Intellectual Property
News headline image
Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics
February 25, 2026
Via MarketMinute
Topics Intellectual Property
News headline image
Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy
February 25, 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Snaps Up Arcellx For $115 Per Share — A $7.8 Billion Bet On Cancer Therapy ↗
February 25, 2026
Via Benzinga
News headline image
Is Amgen Stock Outperforming the Dow?
February 25, 2026
Via Barchart.com
Topics Stocks
News headline image
2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question
February 24, 2026
Via StockStory
News headline image
Gilead Sciences to Present at Upcoming Investor Conferences
February 23, 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Bets Big On Anito-Cel With $7.8 Billion Arcellx Deal ↗
February 23, 2026
Via Investor's Business Daily
News headline image
Gilead Buys Arcellx To Fast-Track Next-Gen Myeloma Drug ↗
February 23, 2026
Via Benzinga
News headline image
Why Did ACLX Stock Surge 80% In Pre-Market Today? ↗
February 23, 2026
Via Stocktwits
News headline image
Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel
February 23, 2026
From Arcellx, Inc.
Via Business Wire
News headline image
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗
February 22, 2026
Via The Motley Fool
News headline image
Where Gilead Sciences Stands With Analysts ↗
February 20, 2026
Via Benzinga
News headline image
Peering Into Gilead Sciences Inc's Recent Short Interest ↗
February 19, 2026
Via Benzinga

Frequently Asked Questions

Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 147.83
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 03/03/26 04:15 PM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 185.35B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 185B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap